Ginsburg, Diane

Diane Ginsburg is a sole proprietorship based in Austin, Texas, registered in SAM.gov since July 2011, specializing in expert witness and pharmaceutical consulting services to federal law enforcement agencies. With a Doctor of Pharmacy degree, Dr. Ginsburg provides specialized support for complex federal investigations involving prescription drug diversion, pharmaceutical compliance, and regulatory matters. Her expertise encompasses detailed analytical work including patient record review, prescription monitoring program analysis, administrative hearing preparation, and expert testimony, positioning her as a trusted resource for federal agencies conducting pharmaceutical-related investigations.

Since 2011, Ginsburg has received over 20 prime federal contract awards exclusively from federal law enforcement and justice agencies, demonstrating a sustained professional relationship focused on expert witness services. Her primary funding agency has been the Drug Enforcement Administration (DEA), which has awarded her the majority of contracts, along with occasional awards from the U.S. Attorney's Offices and the Criminal Division. Contract values have ranged from $1,500 to $18,750, with most structured as time-and-materials or fixed-price purchase orders at a consistent rate of approximately $250 per hour for an estimated 5 to 75 hours of work. Her service scope includes expert review of pharmacy files and prescription data, physician prescription monitoring program analysis, patient record examination, affidavit preparation, file review, trial preparation, administrative hearing preparation, and expert testimony for drug diversion investigations under the DEA's Pharmaceutical Drug Enforcement and Prosecution (GDEP) program. All contracts have been awarded on a non-set-aside basis, reflecting her status as a qualified sole proprietor. Recent awards demonstrate continued engagement, with three active or recently completed contracts from the DEA totaling $34,350 in ceiling value for services rendered between June 2025 and November 2026, underscoring her ongoing role in supporting federal pharmaceutical enforcement operations.